Tonix Pharmaceuticals Holding (TNXP) Profit After Tax (2011 - 2026)

Tonix Pharmaceuticals Holding's Profit After Tax history runs 16 years deep, the most recent figure standing at -$40.3 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 139.68% year-over-year to -$40.3 million in Q1 2026; TTM through Mar 2026 was -$147.3 million, a 9.07% decrease from a year earlier, with the FY2025 full-year figure at -$127.7 million, up 36.02% from the prior year.
• Profit After Tax climbed to -$40.3 million in Q1 2026 per TNXP's latest filing, from -$46.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$14.9 million in Q1 2024 and bottomed at -$78.8 million in Q2 2024.
• The 5-year median for Profit After Tax is -$28.0 million (2023), against an average of -$30.1 million.
• Across the five-year window, Profit After Tax sank 177.81% in 2024 and jumped 64.11% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$15.1 million in 2022, then tumbled by 80.4% to -$27.3 million in 2023, then increased by 17.47% to -$22.5 million in 2024, then slumped by 107.65% to -$46.8 million in 2025, then advanced by 13.86% to -$40.3 million in 2026.
• Per Business Quant, the three latest TNXP Profit After Tax figures stand at -$40.3 million (Q1 2026), -$46.8 million (Q4 2025), and -$31.9 million (Q3 2025).